Alliancebernstein L.P. Kiniksa Pharmaceuticals, Ltd. Transaction History

Alliancebernstein L.P.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$14.37 - $19.07 $33,625 - $44,623	-2,340 Reduced 5.58%	39,560 $693,000
Q3 2022 Nov 15, 2022	BUY	$9.76 - $13.41 $55,632 - $76,437	5,700 Added 15.75%	41,900 $538,000
Q2 2022 Aug 15, 2022	BUY	$7.6 - $11.41 $47,120 - $70,742	6,200 Added 20.67%	36,200 $351,000
Q1 2022 May 13, 2022	BUY	$9.3 - $12.37 $930 - $1,237	100 Added 0.33%	30,000 $298,000
Q4 2021 Feb 14, 2022	BUY	$10.39 - $15.15 $10,390 - $15,150	1,000 Added 3.46%	29,900 $352,000
Q3 2021 Nov 10, 2021	SELL	$11.39 - $16.23 $42,143 - $60,051	-3,700 Reduced 11.35%	28,900 $329,000
Q2 2021 Jul 30, 2021	BUY	$13.22 - $19.09 $140,132 - $202,354	10,600 Added 48.18%	32,600 $454,000
Q1 2021 May 06, 2021	SELL	$16.68 - $23.97 $128,436 - $184,569	-7,700 Reduced 25.93%	22,000 $407,000
Q4 2020 Feb 08, 2021	BUY	$14.8 - $21.15 $20,720 - $29,609	1,400 Added 4.95%	29,700 $525,000
Q3 2020 Nov 12, 2020	SELL	$15.21 - $25.53 $18,252 - $30,636	-1,200 Reduced 4.07%	28,300 $434,000
Q2 2020 Aug 13, 2020	BUY	$15.08 - $26.0 $54,288 - $93,600	3,600 Added 13.9%	29,500 $752,000
Q1 2020 May 14, 2020	BUY	$11.0 - $19.76 $73,700 - $132,392	6,700 Added 34.9%	25,900 $401,000
Q3 2019 Nov 14, 2019	BUY	$8.15 - $15.88 $43,195 - $84,164	5,300 Added 38.13%	19,200 $163,000
Q2 2019 Aug 14, 2019	BUY	$13.2 - $20.39 $183,480 - $283,421	13,900 New	13,900 $188,000
Q1 2019 May 14, 2019	SELL	$15.93 - $26.59 $140,184 - $233,992	-8,800 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$16.25 - $28.09 $143,000 - $247,192	8,800 New	8,800 $247,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.